Skip to main content

Table 1 Baseline characteristics at enrollment

From: Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial

 

AS-SMP

3 days

(N = 476)

AS-SMP

24 hours

(N = 458)

AL

3 days

(N = 450)

Age (Years)

   

   Median

8.0

9.0

8.0

   Min, Max

0.4, 63.5

0.6, 79.0

0.6, 60.0

Age Group (Years)

   

   < 5 – n (%)

153 (32.1)

123 (26.9)

137 (30.4)

Gender

   

   Male – n (%)

239 (50.3)

226 (49.3)

223 (49.6)

P. falciparum (/μl)

   

   Median (IQR)

8400 (3180–24160)

8000 (3200–19520)

7600 (3120–28140)

Gametocyte carriage – n (%)

6 (1.3)

16 (3.5)

8(1.8)

Fever prevalence* – n (%)

332(69.7)

324(70.7)

316(70.2)

  1. N = effective; Std Dev = standard deviation ; IQR = interquartile range
  2. Fever = temperature ≥37.5°C at enrollment